FDA Grants Priority Review to Sanofi's Venglustat for Rare Gaucher Disease

Key Facts

In a move that strengthens Sanofi's position in the rare disease sector, the US FDA has granted priority review to the New Drug Application for venglustat. According to reports, this oral therapy targets Type 3 Gaucher disease, a rare and complex genetic disorder. Priority review status is typically reserved for drugs that offer significant improvements over existing treatments for serious conditions.

This regulatory milestone arrives amid intense competition in the rare disease market, where major peer Takeda reported a 7.1% revenue growth in its rare genetics unit for 2023 per its financial filings. Sanofi is increasingly pivoting toward specialty care to offset patent cliffs, with its specialty care segment generating approximately 18 billion euros in sales last year according to company financial data.